Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Laimer, D; Dolznig, H; Kollmann, K; Vesely, PW; Schlederer, M; Merkel, O; Schiefer, AI; Hassler, MR; Heider, S; Amenitsch, L; Thallinger, C; Staber, PB; Simonitsch-Klupp, I; Artaker, M; Lagger, S; Turner, SD; Pileri, S; Piccaluga, PP; Valent, P; Messana, K; Landra, I; Weichhart, T; Knapp, S; Shehata, M; Todaro, M; Sexl, V; Höfler, G; Piva, R; Medico, E; Ruggeri, BA; Cheng, M; Eferl, R; Egger, G; Penninger, JM; Jaeger, U; Moriggl, R; Inghirami, G; Kenner, L.
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
Nat Med. 2012; 18(11):1699-1704 Doi: 10.1038/nm.2966 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Kenner Lukas; Vesely Paul
Co-authors Med Uni Graz: Höfler Gerald; Staber Philipp
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin's lymphoma found in children and young adults. ALCLs frequently carry a chromosomal translocation that results in expression of the oncoprotein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). The key molecular downstream events required for NPM-ALK-triggered lymphoma growth have been only partly unveiled. Here we show that the activator protein 1 family members JUN and JUNB promote lymphoma development and tumor dissemination through transcriptional regulation of platelet-derived growth factor receptor-β (PDGFRB) in a mouse model of NPM-ALK-triggered lymphomagenesis. Therapeutic inhibition of PDGFRB markedly prolonged survival of NPM-ALK transgenic mice and increased the efficacy of an ALK-specific inhibitor in transplanted NPM-ALK tumors. Notably, inhibition of PDGFRA and PDGFRB in a patient with refractory late-stage NPM-ALK(+) ALCL resulted in rapid, complete and sustained remission. Together, our data identify PDGFRB as a previously unknown JUN and JUNB target that could be a highly effective therapy for ALCL.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Animals -; Benzamides -; Cell Line, Tumor -; Gene Expression Regulation, Neoplastic - drug effects; Humans -; Imatinib Mesylate -; Lymphoma, Large-Cell, Anaplastic - drug therapy Lymphoma, Large-Cell, Anaplastic - metabolism Lymphoma, Large-Cell, Anaplastic - pathology; Mice -; Mice, Transgenic -; Molecular Targeted Therapy -; Neoplasm Staging -; Nuclear Proteins - genetics Nuclear Proteins - metabolism; Oncogene Protein p65(gag-jun) - genetics Oncogene Protein p65(gag-jun) - metabolism; Piperazines - administration & dosage; Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism; Pyrimidines - administration & dosage; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Receptor Protein-Tyrosine Kinases - genetics Receptor Protein-Tyrosine Kinases - metabolism; Receptor, Platelet-Derived Growth Factor alpha - antagonists & inhibitors Receptor, Platelet-Derived Growth Factor alpha - genetics Receptor, Platelet-Derived Growth Factor alpha - metabolism; Receptor, Platelet-Derived Growth Factor beta - antagonists & inhibitors Receptor, Platelet-Derived Growth Factor beta - genetics Receptor, Platelet-Derived Growth Factor beta - metabolism; Remission Induction -; Stem Cell Transplantation -; Transcription Factor AP-1 - genetics Transcription Factor AP-1 - metabolism; Translocation, Genetic -